Claims
- 1. An isolated polynucleotide comprising a polynucleotide having at least 95% identity to a member selected from the group consisting of:
(a) a polynucleotide encoding a polypeptide comprising amino acid 1 to 82 of SEQ ID NO:2; and (b) the complement of (a).
- 2. The isolated polynucleotide of claim 1 wherein said member is (a).
- 3. The isolated polynucleotide of claim 1 wherein said member is (a) and the polypeptide comprises amino acids 1 to 111 of SEQ ID NO:2.
- 4. The isolated polynucleotide of claim 1 wherein said member is (a) and the polypeptide comprises amino acids −20 to 111 of SEQ ID NO:2.
- 5. The isolated polynucleotide of claim 1 comprising a polynucleotide encoding a polypeptide comprising the amino acid sequence identical to amino acids 2 to 82 of SEQ ID NO:2.
- 6. The isolated polynucleotide of claim 1, wherein the polynucleotide is DNA.
- 7. The isolated polynucleotide of claim 1 comprising a polynucleotide encoding a polypeptide comprising the amino sequence identical to amino acids 1 to 111 of SEQ ID NO:2.
- 8. The isolated polynucleotide of claim 1, wherein said polynucleotide is RNA.
- 9. A method of making a recombinant vector comprising inserting the isolated polynucleotide of claim 2 into a vector, wherein said polynucleotide is DNA.
- 10. A recombinant vector comprising the polynucleotide of claim 2, wherein said polynucleotide is DNA.
- 11. A recombinant host cell comprising the polynucleotide of claim 2, wherein said polynucleotide is DNA.
- 12. A method for producing a polypeptide comprising expressing from the recombinant cell of claim 11 the polypeptide encoded by said polynucleotide.
- 13. A process for producing a polypeptide comprising:
expressing from a recombinant cell containing the polynucleotide of claim 5 the polypeptide encoded by said polynucleotide.
- 14. A process for producing a polypeptide comprising:
expressing from a recombinant cell containing the polynucleotide of claim 7 the polypeptide encoded by said polynucleotide.
- 15. The isolated polynucleotide of claim 1 comprising nucleotides 202 to 534 of SEQ ID NO:1.
- 16. The isolated polynucleotide of claim 1 comprising nucleotides 142 to 534 of SEQ ID NO:1.
- 17. The isolated polynucleotide of claim 1 comprising nucleotides 202 to 447 of SEQ ID NO:1.
- 18. The isolated polynucleotide of claim 1 comprising the nucleotides of the sequence of SEQ ID NO:1.
- 19. An isolated polynucleotide comprising a polynucleotide having at least a 95% identity to a member selected from the group consisting of:
(a) a polynucleotide encoding the same mature polypeptide encoded by the human cDNA in ATCC Deposit No. 97301; and (b) the complement of (a).
- 20. The isolated polynucleotide of claim 19, wherein the member is (a).
- 21. The isolated polynucleotide of claim 19, wherein said polynucleotide comprises DNA identical to the coding portion of the human cDNA in ATCC Deposit No. 97301 which encodes a mature polypeptide.
- 22. An isolated polypeptide comprising:
a mature polypeptide having an amino acid sequence encoded by a polynucleotide which is at least 95% identical to the polynucleotide of claim 5.
- 23. The isolated polypeptide of claim 22, comprising amino acids 2 to 82 of sequence of SEQ ID NO:2.
- 24. The isolated polypeptide of claim 22, comprising amino acids 1 to 111 of sequence of SEQ ID NO:2.
- 25. The isolated polypeptide of claim 22 comprising amino acids −20 to 111 of SEQ ID NO:2.
- 26. An isolated polypeptide comprising:
a mature polypeptide encoded by a polynucleotide which is at least 95% identical to the human cDNA contained in ATCC Deposit No. 97301.
- 27. The isolated polypeptide of claim 26 comprising the mature polypeptide encoded by the human cDNA in ATCC Deposit No. 97301.
- 28. An antibody against the polypeptide of claim 22.
- 29. An antagonist against the polypeptide of claim 22.
- 30. A method for the treatment of a patient having need of a hSca-2 protein comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 22.
- 31. The method of claim 27 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.
- 32. A method for the treatment of a patient having need to inhibit a hSca-2 protein polypeptide comprising:
administering to the patient a therapeutically effective amount of the compound of claim 29.
- 33. A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of the polypeptide of claim 22 comprising:
determining a mutation in a nucleic acid sequence encoding said polypeptide.
- 34. A diagnostic process comprising: analyzing for the presence of the polypeptide of claim 22 in a sample derived from a host.
- 35. A method for identifying compounds which bind to and inhibit activation of the polypeptide of claim 22 comprising:
contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with an analytically detectable mammary transforming protein and a compound under conditions to permit binding to the receptor; and determining whether the compound binds to and inhibits the receptor by detecting-the absence of a signal generated from the interaction of the hSca-2 protein with the receptor.
- 36. An isolated polynucleotide comprising a member selected from the group consisting of:
(a) DNA having a sequence of at least 15 consecutive bases, which sequence is at least 95% complementary to a member selected from the group consisting of:
(i) DNA having at least 15 consecutive bases from nucleotide 1 to nucleotide 1157 of SEQ ID NO:1; (ii) DNA complementary to (i); and (b) RNA corresponding to the DNA of (a).
- 37. The isolated polynucleotide of claim 36 wherein said member is (a).
- 38. The isolated polynucleotide of claim 36 wherein said member is (b).
- 39. The isolated polynucleotide of claim 37 wherein said member is (a) and said 15 consecutive bases are selected from the sequence of nucleotides 142 to 534.
- 40. An isolated polynucleotide comprising a member selected from the group consisting of:
(a) DNA having a sequence of at least 15 consecutive bases, which sequence is at least 95% complementary to a member selected from the group consisting of:
(i) DNA having at least 15 consecutive bases from the portion of the cDNA of ATCC Deposit No. 97301 which encodes for hSca-2; (ii) DNA complementary to (i); and (b) RNA corresponding to the DNA of (a).
- 41. The isolated polynucleotide of claim 40 wherein said member is (a).
- 42. The isolated polynucleotide of claim 40 wherein said member is (b).
Parent Case Info
[0001] This application is entitled to the benefits of 35 U.S.C. § 120 based on U.S. Provisional Application 60/007,287, filed Nov. 9, 1995, pending.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60007287 |
Nov 1995 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
08746397 |
Nov 1996 |
US |
Child |
09493269 |
Jan 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09493269 |
Jan 2000 |
US |
Child |
10101747 |
Mar 2002 |
US |